Get the Stockscreener App
90.12
5.70%
4.8625
Inhibrx Biosciences Inc stock is traded at $90.12, with a volume of 91,485.
It is up +5.70% in the last 24 hours and down -14.66% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$85.26
Open:
$87.6
24h Volume:
91,485
Relative Volume:
0.43
Market Cap:
$1.33B
Revenue:
$1.30M
Net Income/Loss:
$-130.19M
P/E Ratio:
-10.74
EPS:
-8.3898
Net Cash Flow:
$-131.94M
1W Performance:
-2.84%
1M Performance:
-14.66%
6M Performance:
+7.81%
1Y Performance:
+150.76%
1-Day Range:
$87.20
$90.90
1-Week Range:
$83.61
$96.10
52-Week Range:
$28.16
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
90.12 | 1.33B | 1.30M | -130.19M | -131.94M | -8.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-24-26 | Initiated | H.C. Wainwright | Buy |
| Apr-08-26 | Initiated | Stifel | Buy |
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
Inhibrx Biosciences stock falls 1.62 percent on October 5 - AD HOC NEWS
Form 4 Inhibrx Biosciences Inc For: 28 September By Investing.com - Investing.com Nigeria
Inhibrx Biosciences CEO Mark Lappe buys $998k in company stock - Investing.com Canada
Form 4 Inhibrx Biosciences Inc For: 28 September By Investing.com - Investing.com India
Form 4 Inhibrx Biosciences Inc For: 28 September By Investing.com - Investing.com UK
Four purchases over two days: Inhibrx Biosciences (INBX) CEO's family trust bought 10,000 shares. - Stock Titan
Inhibrx Biosciences CEO Mark Lappe buys $998k in company stock - Investing.com
Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock By Investing.com - Investing.com Nigeria
Form 4 Inhibrx Biosciences Inc For: 23 September - Investing.com India
Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock - Investing.com India
Form 4 Inhibrx Biosciences Inc For: 23 September By Investing.com - Investing.com UK
At $100 a share, a director's family trust bought 5,000 shares of Inhibrx Biosciences (INBX). - Stock Titan
Inhibrx Biosciences Director Kristiina Vuori Receives Corrected Stock Option Grant - Kalkine Media
Inhibrx Biosciences Director Kimberly Manhard Revises Stock Option Grant Filing - Kalkine Media
Director at Inhibrx (NASDAQ: INBX) awarded 10,000 options - Stock Titan
Inhibrx (NASDAQ: INBX) director gets 10,000 options expiring 2036 - Stock Titan
Inhibrx (INBX) corrects director's 10,000-option grant - Stock Titan
Inhibrx (INBX) corrects 10,000-option grant to director - Stock Titan
Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock - Investing.com
Family trust of Inhibrx (INBX) director adds 5,000 shares at $100 - Stock Titan
Director’s trust sells 1,500 Inhibrx (INBX) shares - Stock Titan
Director’s trust at Inhibrx (NASDAQ: INBX) logs four 500-share stock sales - Stock Titan
Inhibrx (NASDAQ: INBX) director's trust files to sell 500 shares - Stock Titan
Founder of Inhibrx Biosciences Mark Lappe Buys 2.7% More Shares - webull.com
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock By Investing.com - Investing.com South Africa
Director trust at Inhibrx (INBX) proposes $55.9K stock sale - Stock Titan
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock By Investing.com - Investing.com Australia
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock By Investing.com - Investing.com UK
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock - Investing.com
Inhibrx Biosciences Director Kimberly Manhard Sells 1,000 Shares via Revocable Trust in September 2026 - Kalkine Media
Director’s trust at Inhibrx Biosciences (INBX) sells 1,000 shares in two days - Stock Titan
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL) - The Globe and Mail
Founder of Inhibrx Biosciences Mark Lappe Buys 2.7% More Shares - simplywall.st
Founder of Inhibrx Biosciences Mark Lappe Buys 2.7% More Shares - simplywall.st
Inhibrx director Jon Kayyem buys $567,580 in company stock By Investing.com - Investing.com South Africa
Director-linked trust plans $57.9K INBX stock sale - Stock Titan
Inhibrx, Eikon rise after insider buying - TradingView
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy - Investing.com
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy By Investing.com - Investing.com Canada
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom (NASDAQ:INBX) - Seeking Alpha
Inhibrx director Jon Kayyem buys $567,580 in company stock By Investing.com - Investing.com Australia
Inhibrx director Jon Kayyem buys $567,580 in company stock By Investing.com - Investing.com Canada
Inhibrx (INBX) investor files notice to sell 500 shares - Stock Titan
Family trust tied to Inhibrx (INBX) director buys more stock in open market - Stock Titan
Inhibrx Biosciences reports strong Phase 2 INBRX-106 data - TipRanks
Inhibrx (INBX) director buys 2,500 shares via family trust - Stock Titan
Inhibrx Biosciences (INBX) chief boosts stake with 25,000-share buy - Stock Titan
80% response in HPV+ head and neck cancer lifts Inhibrx (INBX) trial plans - Stock Titan
Why Inhibrx Biosciences (INBX) Stock Is Down Today - Quiver Quantitative
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates - Benzinga
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inhibrx Biosciences Inc Stock (INBX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lappe Mark | Chief Executive Officer |
Sep 28 '26 |
Buy |
100.76 |
4,500 |
453,426 |
740,548 |
| Kayyem Jon Faiz | Director |
Sep 23 '26 |
Buy |
100.00 |
5,000 |
500,000 |
434,360 |
| Kayyem Jon Faiz | Director |
Sep 16 '26 |
Buy |
100.00 |
5,000 |
500,000 |
429,360 |
| MANHARD KIMBERLY | Director |
Sep 15 '26 |
Sale |
105.05 |
500 |
52,525 |
7,500 |
| MANHARD KIMBERLY | Director |
Sep 15 '26 |
Proposed Sale |
105.05 |
500 |
52,525 |
0 |
| MANHARD KIMBERLY | Director |
Sep 14 '26 |
Proposed Sale |
110.26 |
500 |
55,130 |
0 |
| MANHARD KIMBERLY | Director |
Sep 14 '26 |
Sale |
110.26 |
500 |
55,130 |
8,000 |
| MANHARD KIMBERLY | Director |
Sep 11 '26 |
Proposed Sale |
111.78 |
500 |
55,888 |
0 |
| MANHARD KIMBERLY | Director |
Sep 11 '26 |
Sale |
111.78 |
500 |
55,888 |
8,500 |
| MANHARD KIMBERLY | Director |
Sep 09 '26 |
Proposed Sale |
115.80 |
500 |
57,898 |
0 |
2.33%
2.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):